Profile data is unavailable for this security.
About the company
Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.
- Revenue in PLN (TTM)337.26m
- Net income in PLN65.30m
- Incorporated2019
- Employees387.00
- LocationSelvita SAHexagon, Ul. Podole 79KRAKOW 30-394PolandPOL
- Phone+48 123005001
- Fax+48 122974701
- Websitehttps://selvita.com/
More ▼
Mergers & acquisitions
| Acquired company | SLV:WSE since announced | Transaction value |
|---|---|---|
| PozLab Sp z o o | 11.11% | 6.29m |
Data delayed at least 15 minutes, as of Jul 05 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioInvent International AB | 23.06m | -126.14m | 806.42m | 109.00 | -- | 1.74 | -- | 34.97 | -5.08 | -5.08 | 0.929 | 18.73 | 0.041 | -- | 1.29 | 550,927.90 | -22.41 | -17.50 | -23.68 | -18.64 | -- | -- | -547.02 | -131.63 | 13.34 | -- | 0.0169 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
| Vicore Pharma Holding AB | 39.31m | -80.29m | 808.93m | 26.00 | -- | 4.39 | -- | 20.58 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Genfit SA | 163.52m | -123.76m | 817.64m | 159.00 | -- | 2.81 | -- | 5.00 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| XSpray Pharma AB (publ) | 0.00 | -80.16m | 832.55m | 26.00 | -- | 4.01 | -- | -- | -7.66 | -7.66 | 0.00 | 20.00 | 0.00 | -- | -- | 0.00 | -33.92 | -18.38 | -36.11 | -19.26 | -- | -- | -- | -- | 2.24 | -- | 0.0536 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Sensorion SA | 0.00 | -94.50m | 877.81m | 50.00 | -- | 3.83 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
| hVIVO PLC | 283.72m | 81.58m | 954.11m | 274.00 | 11.84 | 5.49 | 10.01 | 3.36 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Molecular Partners AG | 29.66m | -258.12m | 985.19m | 168.00 | -- | 1.19 | -- | 33.21 | -1.78 | -1.78 | 0.2043 | 5.13 | -- | -- | -- | 40,035.71 | -- | -11.83 | -- | -14.69 | -- | 99.28 | -870.22 | -45.30 | -- | -- | 0.0195 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Nanobiotix SA | 128.75m | -170.04m | 985.19m | 102.00 | -- | -- | -- | 7.65 | -1.10 | -1.10 | 0.814 | -0.0391 | 0.3912 | -- | 19.59 | 294,686.30 | -51.67 | -54.11 | -120.56 | -80.68 | -- | -- | -132.08 | -756.15 | -- | -1.98 | 1.04 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
| 4Basebio PLC | 2.56m | -38.80m | 1.01bn | -- | -- | -- | -- | 396.05 | -0.6222 | -0.6222 | 0.0411 | -0.0399 | 0.0429 | 0.714 | 6.29 | -- | -64.93 | -- | -77.36 | -- | 67.19 | -- | -1,514.82 | -- | 2.06 | -26.66 | 1.05 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| Ryvu Therapeutics SA | 55.61m | -93.91m | 1.14bn | 230.00 | -- | 5.86 | -- | 20.58 | -4.10 | -4.10 | 2.42 | 8.45 | 0.1302 | 12.39 | 4.99 | 241,760.90 | -21.99 | -21.88 | -24.87 | -25.20 | 56.80 | -6.28 | -168.89 | -284.20 | 4.71 | -- | 0.1193 | -- | 20.32 | -9.50 | -9.94 | -- | 53.71 | -- |
| Allergy Therapeutics plc | 269.62m | -254.22m | 1.15bn | 635.00 | -- | 8.56 | -- | 4.25 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Bioventix PLC | 68.83m | 43.87m | 1.17bn | 16.00 | 27.11 | 20.20 | 26.28 | 16.99 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
| Avacta Group Plc | 117.69m | -126.30m | 1.23bn | 154.00 | -- | -- | -- | 10.47 | -0.0914 | -0.0914 | 0.0853 | -- | -- | -- | -- | 150,954.50 | -- | -- | -- | -- | 48.37 | -- | -107.31 | -- | -- | -0.575 | -- | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| Hansa Biopharma AB | 62.55m | -318.58m | 1.24bn | 166.00 | -- | -- | -- | 19.81 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Selvita SA | 337.26m | 65.30m | 1.25bn | 387.00 | 19.12 | 3.81 | 11.07 | 3.70 | 3.56 | 3.56 | 18.37 | 17.83 | 0.553 | 9.29 | 4.70 | 398,178.30 | 10.71 | -- | 12.99 | -- | 79.66 | -- | 19.36 | -- | 1.41 | 11.34 | 0.4063 | -- | -3.48 | -- | 130.55 | -- | -- | -- |
| Nykode Therapeutics ASA | 41.87m | -156.91m | 1.65bn | 176.00 | -- | 2.63 | -- | 39.32 | -1.40 | -1.40 | 0.3714 | 5.13 | 0.0534 | -- | 91.80 | 646,936.30 | -20.01 | 5.65 | -22.97 | 6.38 | -- | -- | -374.77 | 18.13 | -- | -- | 0.0313 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
Data as of Jul 05 2024. Currency figures normalised to Selvita SA's reporting currency: Polish New Zloty PLN
39.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nationale-Nederlanden PTE SAas of 08 Nov 2022 | 1.90m | 10.36% |
| Allianz Polska TFI SAas of 08 Nov 2022 | 1.80m | 9.82% |
| FORUM TFI SAas of 21 Nov 2022 | 847.74k | 4.62% |
| Allianz Polska PTE SAas of 29 Dec 2023 | 823.92k | 4.49% |
| Vienna PTE SA Vienna Insurance Groupas of 31 Dec 2021 | 639.76k | 3.49% |
| Generali PTE SAas of 29 Dec 2023 | 325.18k | 1.77% |
| PKO TFI SAas of 31 Oct 2023 | 290.74k | 1.58% |
| Investors TFI SAas of 31 Dec 2022 | 271.75k | 1.48% |
| Pekao TFI SAas of 31 Dec 2023 | 141.36k | 0.77% |
| TFI PZU SAas of 30 Jun 2023 | 131.70k | 0.72% |
More ▼
Data from 31 Dec 2021 - 30 Apr 2024Source: FactSet Research Systems Inc.
